Non-internalising antibody-drug conjugates

Antibody-drug conjugates (ADCs) typically require internalisation into cancer cells to release their cytotoxic payload. However, this places stringent constraints on therapeutic development, requiring cancer targets that have high expression of internalising antigens and efficient intracellular processing. An alternative approach is emerging whereby the payloads can be released extracellularly from cleavable linkers upon binding to poorly-internalising antigens or other tumoral components. This removes the reliance on high antigen expression, avoids potentially inefficient internalisation, and can greatly expand the range of cancer targets to components of the extracellular tumour matrix. This review gives an overview of recent developments towards non-internalising ADCs, including emerging cancer-associated cell surface and extracellular proteins, cancer stromal targeting and the linking chemistry that enables extracellular payload release.

Automated summary

Traditional antibody-drug conjugates (ADCs) require internalisation into cancer cells, but this approach has limitations. Recent research has shown that extracellular release of drugs upon binding to poorly-internalising antigens or other tumoral components can overcome these limitations. This new approach has the potential to expand the range of cancer targets and improve treatment efficacy.